featured
First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Advanced Extranodal Natural Killer/T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
Lancet Haematol 2024 Mar 27;[EPub Ahead of Print], XP Tian, J Cai, Y Xia, YC Zhang, L Wang, PP Liu, HQ Huang, YJ Li, H Zhou, ZM Li, J Yang, LQ Wei, QH Zou, Y Huang, J Li, L Ling, WL Zhong, QQ CaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.